A randomized controlled trial of the efficacy and safety of saxagliptin as add‐on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Abstract

Addition of saxagliptin 5 mg/day in patients inadequately controlled on metformin and sulphonylurea effectively improved glycaemic control and was well tolerated.